SAVE THE DATE:
You and your endocrinology and diabetes specialist colleagues are invited to
An ATTD 2024 CME Expert Board Satellite Symposium on
Join the Experts for an Interactive Clinic in CGM-Directed
Case Management in Persons with Type 2 and Type 1 Diabetes
Save the Date and Time – Register Now!
Wednesday, 6 March, 2024
Lunch and Registration: 14:00 – 14:30
Scientific Program: 14:30 – 16:00
Location: Fortezza da Basso
Room: Hall E
For more information:
info@cmeducation.net
Program Agenda
14:30 – 14:45
Program Chairperson’s Introduction
The Role of CGM for Identifying New Glycemic Metric “Destinations” Beyond HbA1c
A Clinical Success Roadmap for Improving Outcomes Across the Type 2 and Type I Spectrum of Care
Richard Bergenstal, MD – Program Chair
Executive Director
Park Nicollet International Diabetes Center
Adjunct Professor, Department of Medicine
University of Minnesota
St. Louis Park, MN
14:45 – 15:10
Part 1: The Actionability of Ambulatory Glucose Profiles (AGP) for Guiding Therapeutic Decisions on T2D Part 2: Interactive Case-Based Clinic with CGM Experts Board
AGP Interpretation and Therapeutic Interventions Guided by CGM Readouts Applied at the Front Lines of Diabetes Care
Richard Bergenstal, MD – Program Chair
Executive Director
Park Nicollet International Diabetes Center
Adjunct Professor, Department of Medicine
University of Minnesota
St. Louis Park, MN
15:10 – 15:35
Part 1: Dual Ketone and Glucose CGM Monitoring for Integration with Insulin Delivery/Pump Systems Part 2: Interactive Case-Based Clinic with CGM Experts Board
Applying Dual Monitoring Capabilities to Patient Care Across the Diabetes Age Spectrum
Jennifer L. Sherr, MD, PhD
Professor of Pediatrics, Pediatric Endocrinology Yale University School of Medicine One Long Wharf Drive, Suite 503 New Haven, CT
15:35 – 16:00
Part 1: Applying Technological Advances in CGM to Move Beyond HbA1c in Older Persons with T2D Part 2: Interactive Cased-Based Clinic with CGM Experts Board Focuses on Optimizing Therapeutic in Vulnerable Persons with Diabetes
Medha Munshi, MD
Director of Joslin Geriatric Diabetes Programs Geriatrician, Beth Israel Deaconess Medical Center Associate Professor of Medicine, Harvard Medical School Brookline, MA
Program Chair and Distinguished Faculty
Richard Bergenstal, MD
— Program Chair
Executive Director
Park Nicollet International Diabetes Center
Adjunct Professor, Department of Medicine
University of Minnesota
St. Louis Park, MN
Jennifer L. Sherr, MD, PhD
Professor of Pediatrics, Pediatric Endocrinology
Yale University School of Medicine
New Haven, CT
Medha Munshi, MD
Director of Joslin Geriatric Diabetes Programs
Geriatrician, Beth Israel Deaconess Medical Center
Associate Professor of Medicine, Harvard Medical School
Brookline, MA
EDUCATIONAL AND LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
- Outline and discuss the evidentiary basis for sensor-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for persons with T2D and T1D within the diabetes and endocrinology specialty setting.
- Analyze the rationale and evidence for recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies.
- Compare and contrast available CGM-facilitating monitoring technologies and pair such technologies with optimal patient profiles.
- Educate persons with diabetes about the rationale, evidence, and outcome- optimizing results associated with technology-based, patient-centric and physician-directed CGM monitoring strategies that can be used to effect .optimal lifestyle, diet-, and pharmacology-based approaches to attaining guideline-based HA1c levels in persons with T2D and T1D.
- Identify which persons with diabetes are ideal candidates for a technology-based, patient-directed glucose monitoring system.
- Interpret and apply data and results from clinical trials in CGM-facilitating monitoring technologies to improve patient care, improve safety of drug therapy for T2D and T1D, detect and mitigate risk of hypoglycemia, improve patient- and physician-directed changes in antidiabetic therapy, reinforce the safe use of antidiabetic drugs, and facilitate patient-activated drug titration, glycemic monitoring and disease management.
- Translate landmark clinical studies focused on CGM-based technologies to the front lines of clinical practice in the diabetes and primary care; and understand the translational implications of deploying sensor-based CGM technologies as a foundational approach to improving outcomes in patients across the spectrum of diabetes.
TARGET AUDIENCE — WHO SHOULD ATTEND
This Clinical Excellence Summit is directed at the following: diabetes and endocrinology specialists and researchers and related healthcare providers who manage patients with Type 2 or Type 1 diabetes.
GRANTOR SUPPORT
Supported by an educational grant from Abbott Diabetes Care.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Chan Medical School and CMEducation Resources, LLC. The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The University of Massachusetts Chan Medical School designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
FACULTY & PROVIDER DISCLOSURE
It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
———